ITPase gene polymorphisms associated with adverse drug...

Details ITPase gene polymorphisms associated with adverse drug... ITPase gene polymorphisms associated with adverse drug...

2011-07-05

2011-07-05

Pohnert, Steven C (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C536S024300, C435S091200

Reexamination Certificate

active

07972780

ABSTRACT:
The present invention provides methods for predicting a patient's risk of an adverse drug reaction to a thiopurine drug such as AZA or 6-MP by genotyping the patient for a polymorphism in the gene encoding ITPase (ITPA). The present invention also provides methods for predicting a patient's risk of an adverse drug reaction to a thiopurine drug by determining a level of ITPase activity or ITP in a sample from the patient. The present invention further provides methods for optimizing therapeutic efficacy in a patient receiving a thiopurine drug by determining whether the patient should be given an alternative drug based on the presence or absence of a polymorphism in the ITPA gene.

REFERENCES:
Sumi et al, Human Genetics (2002) vol. 111, pp. 360-367.
Gearry et al (Pharmacogenetics (2004) vol. 14, pp. 779-781.
De Ridder et al, Ailment Pharmacology Therapy (2006) vol. 23, pp. 1137-1141.
Sumi et al ( Human Genetics (2002) vol. 111, pp. 360-367).
Kader et al (Journal of Clinical Gastroenterology (2000) pp. 409-413).
Zelinkova et al ( Clinical Gastroenterology and Hepatology (2006) pp. 44-49).
von Ashen et al (Clinical Chemistry (2005) vol. 51, pp. 2282-2288).
Stenmark et al ( Journal of Biological chemistry (2007) vol. 282, pp. 3182-3187).
Van Dieren et al ( Alimentary Pharmacology & therapeutics (2007) vol. 26, pp. 643-652).
Palmieri et al (Alimentary Pharmacology & therapeutics (2007) vol. 26, pp. 737-745).
Hirschhorn et al. (Genetics in Medicine. vol. 4, No. 2, pp. 45-61, Mar. 2002).
Ioannidis (Nature Genetics, vol. 29, pp. 306-309, Nov. 2001).
A.M. Marinaki, et al., Mutation in the ITPA Gene Predicts Intolerance to Azathioprine; Nucleosides Nucleotides Nucleic Acids; Oct. 2004; 23(8-9): 1392-7; PMID: 15571265.
Ansari A.; Pharmacogenetic profiling in azathioprine treatment: TPMT, ITPA, and MTHRF polymorphisms and toxicity; GUT; Apr. 2004; p. A105; vol. 53; No. Suppl. 3; Scotland, UK.
Marinaki A.M. et al.; Allele frequency of inosine triphosphate pyrophosphatase gene polymorphisms in a Japanese population; Nucleosides Nudeotides & Nucleic Acids; Oct. 2004; pp. 1399-1401; vol. 23, No. 8-9.
Heller T. et al.; Rapid detection of ITPA 94C>A and IVS2 + 21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2 + 21A>C polymorphism on splicing efficiency; Clinical Chemistry; 2004: pp. 2182-2184; vol. 50, No. 11.
Marsh Sharon et al.; Distribution of ITPA P32T alleles in multiple world populations; Journal of Human Genetics; Oct. 2004; pp. 579-581; vol. 49, No. 10.
Ansari Azhar R. et al.; Mutation in the ITPA gene predicts intolerance to azathiooprine: Digestive Disease Week Abstracts and Itinerary Planner; May 2003; p. 89; vol. 2003.
Marinaki A. et al.; Mutation in the ITPA gne predicts intolerance to azathioprine; GUT; Apr. 2003; p. A13; vol. 52, No. Suppl. 1; Birmingham, England.
Cao Henian et al.; DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency: Journal of Human Genetics; 2002: pp. 620-622; vol. 47, No. 11.
Duley J.A. et al.; ITPA polymorphism predicts thiopurine intolerance; Journal of Inherited Metabolic Disease; Sep. 2003; p. 129; vol. 26, No. Suppl. 2; Brisbane Australia.
Gearry Richard B. et al.; Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine; Pharmacogenetics; Nov. 2004; pp. 779-781; vol. 14, No. 11.
Allorge D. et al.; ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuprression; GUT; Apr. 2005; p. 565; vol. 54, No. 4.
S.Sumi, et al.; Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency; Hum Genet (2002) 111: 360-367; Springer-Verlag 2002.
A. Marinaki, et al.; Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase); Pharmacogenetics 2004, 14:181-187, vol. 14, No. 3; Lippincott Williams & Wilkins.
A. Marinaki, et al.; Mutation in the ITPA gene predicts intolerance to azathioprine; Nucleosides Nucleotides Nucleic Acids; Oct. 2004; 23 (8-9): 1393-7; PMID: 15571265 (Abstract only).
Stocco, G. “Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia,” Nature Publishing Group, 2009, vol. 85, No. 2, pp. 164-172.
Uchiyama, Kan, “ThiopurineS-methyltransferase and inosine triphosphate pyrophosphohyrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment,” J. Gastroenterol., 2009, vol. 44, pp. 197-203.

Affiliated with

Also associated with

Rating

ITPase gene polymorphisms associated with adverse drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with ITPase gene polymorphisms associated with adverse drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ITPase gene polymorphisms associated with adverse drug... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2664086